BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38367794)

  • 41. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.
    Jingjing Z; Lei M; Jie Z; Sha C; Yapeng H; Weimin Z; Chunluan Y
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1549-1558. PubMed ID: 31900516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.
    Chen JL; Chu PY; Huang CT; Huang TT; Wang WL; Lee YH; Chang YY; Dai MS; Shiau CW; Liu CY
    Mol Med; 2022 Aug; 28(1):93. PubMed ID: 35941532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
    Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
    Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
    Mathas S; Hinz M; Anagnostopoulos I; Krappmann D; Lietz A; Jundt F; Bommert K; Mechta-Grigoriou F; Stein H; Dörken B; Scheidereit C
    EMBO J; 2002 Aug; 21(15):4104-13. PubMed ID: 12145210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
    Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
    Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 53. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas.
    Papoudou-Bai A; Goussia A; Batistatou A; Stefanou D; Malamou-Mitsi V; Kanavaros P
    Leuk Lymphoma; 2016; 57(1):143-50. PubMed ID: 25813203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma.
    Thoennissen NH; Thoennissen GB; Abbassi S; Nabavi-Nouis S; Sauer T; Doan NB; Gery S; Müller-Tidow C; Said JW; Koeffler HP
    Leuk Lymphoma; 2012 Aug; 53(8):1577-85. PubMed ID: 22260161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
    Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
    Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel cyclophosphamide of natural products osalmide and pterostilbene induces cytotoxicity and cell cycle arrest in diffuse large B-cell lymphoma cells.
    Xi M; He W; Li B; Zhou J; Xu Z; Wu H; Zhang Y; Song D; Hu L; Lu Y; Bu W; Kong Y; Chen G; Chang S; Shi J; Zhu W
    Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):401-410. PubMed ID: 32259210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.
    Li X; He Z; Cheng B; Fang Q; Ma D; Lu T; Wei D; Kuang X; Tang S; Xiong J; Wang J
    Cancer Biol Ther; 2018; 19(9):825-834. PubMed ID: 29969367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
    Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
    Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.